keyword
MENU ▼
Read by QxMD icon Read
search

Her 2 positive Breast cancer

keyword
https://www.readbyqxmd.com/read/29146401/neratinib-after-trastuzumab-based-adjuvant-therapy-in-her2-positive-breast-cancer-extenet-5-year-analysis-of-a-randomised-double-blind-placebo-controlled-phase-3-trial
#1
Miguel Martin, Frankie A Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gunter von Minckwitz, Stephen K L Chia, Janine Mansi, Carlos H Barrios, Michael Gnant, Zorica Tomašević, Neelima Denduluri, Robert Šeparović, Erhan Gokmen, Anna Bashford, Manuel Ruiz Borrego, Sung-Bae Kim, Erik Hugger Jakobsen, Audrone Ciceniene, Kenichi Inoue, Friedrich Overkamp, Joan B Heijns, Anne C Armstrong, John S Link, Anil Abraham Joy, Richard Bryce, Alvin Wong, Susan Moran, Bin Yao, Feng Xu, Alan Auerbach, Marc Buyse, Arlene Chan
BACKGROUND: ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast cancer. We report updated efficacy outcomes from a protocol-defined 5-year follow-up sensitivity analysis and long-term toxicity findings. METHODS: In this ongoing randomised, double-blind, placebo-controlled, phase 3 trial, eligible women aged 18 years or older (≥20 years in Japan) with stage 1-3c (modified to stage 2-3c in February, 2010) operable breast cancer, who had completed neoadjuvant and adjuvant chemotherapy plus trastuzumab with no evidence of disease recurrence or metastatic disease at study entry...
November 13, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29142588/characterization-of-hormonal-receptors-and-human-epidermal-growth-factor-receptor-2-in-tissues-of-women-with-breast-cancer-at-muhimbili-national-hospital-dar-es-salaam-tanzania
#2
Amos Rodger Mwakigonja, Nyanda Elias Lushina, Ally Mwanga
Background: Breast cancer is a leading cause of morbidity and deaths among women worldwide. In Tanzania there is no published data on human epidermal growth receptor-2 (HER2/neu) expression in breast carcinoma. Hormonal receptors and HER2/neu status reportedly influence post-mastectomy adjuvant therapy and predict treatment outcome and prognosis. Here we evaluate hormonal receptors and HER-2 status in biopsies of women with breast cancer at Muhimbili National Hospital (MNH). Methods: A cross-sectional study of female breast post-modified radical mastectomy (MRM)/incisional biopsies confirmed to be carcinoma at the Histopathology Unit (January-December 2013)...
2017: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/29137365/longitudinal-serum-metabolomics-evaluation-of-trastuzumab-and-everolimus-combination-as-pre-operative-treatment-for-her-2-positive-breast-cancer-patients
#3
Elodie Jobard, Olivier Trédan, Thomas Bachelot, Arnaud M Vigneron, Céline Mahier Aït-Oukhatar, Monica Arnedos, Maria Rios, Jacques Bonneterre, Véronique Diéras, Marta Jimenez, Jean-Louis Merlin, Mario Campone, Bénédicte Elena-Herrmann
The mammalian target of rapamycin complex 1 (mTORC1) is an attractive target for HER-2 positive breast cancer therapy because of its key role in protein translation regulation, cell growth and metabolism. We present here a metabolomic investigation exploring the impact of mTOR inhibition on serum metabolic profiles from patients with non-metastatic breast cancer overexpressing HER-2. Baseline, treatment-related and post-treatment serum samples were analyzed for 79 patients participating in the French clinical trial RADHER, in which randomized patients with HER-2 positive breast cancer received either trastuzumab alone (arm T) or a trastuzumab and everolimus combination (arm T+E)...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29136066/unsuspected-lymphomatoid-granulomatosis-in-a-patient-with-antisynthetase-syndrome
#4
Stephanie L Skala, Alexandra C Hristov, Johann E Gudjonsson, May P Chan
Clinical diagnosis of lymphomatoid granulomatosis (LYG) often is difficult, especially in patients with multiple comorbidities. We present a 60-year-old woman with worsening fatigue, night sweats, unintentional weight loss, and dyspnea of 2 weeks' duration. Her medical history was remarkable for recent radiation therapy for recurrent breast cancer and antisynthetase syndrome complicated by interstitial lung disease and controlled with azathioprine. Computed tomography showed ground-glass opacities and nodular infiltrates in all lung lobes, raising concern for radiation pneumonitis and drug toxicity...
October 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/29135102/changes-in-18f-fdg-pet-ct-tumor-metabolism-are-not-consistent-with-pathologic-complete-response-in-hormone-positive-breast-cancer
#5
Serap Kaya, Bilge Aktas, Eda Tanrikulu Sismek, Mehmet Akif Ozturk, Fuat Dede, Handan Kaya, Umit Ugurlu, Zerrin Ozgen, Sinan Koca, Suleyman Halil, Rahib Hasanov, Ozkan Alan, Nalan Akgul Babacan, Ozlem Ercelep, Faysal Dane, Mahmut Gumus, Fulden Yumuk
PURPOSE: Current evaluation of response to neoadjuvant chemotherapy (NAC) shows that it could achieve pathological complete response (pCR). The purpose of this study was to assess the consistency of maximum uptake values (SUVmax) changes and pCR in hormone-positive locally advanced breast cancer (LABC). METHODS: Ninety hormone-positive LABC patients treated at Marmara University Medical Oncology Clinic, Istanbul, Turkey, between 2009 and 2015 were retrospectively studied...
September 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29127433/targeting-and-suppression-of-her3-positive-breast-cancer-by-t-lymphocytes-expressing-a-heregulin-chimeric-antigen-receptor
#6
Bai-Le Zuo, Bo Yan, Guo-Xu Zheng, Wen-Jin Xi, Xiao Zhang, An-Gang Yang, Lin-Tao Jia
Chimeric antigen receptor-modulated T lymphocytes (CAR-T) have emerged as a powerful tool for arousing anticancer immunity. Endogenous ligands for tumor antigen may outperform single-chain variable fragments to serve as a component of CARs with high cancer recognition efficacy and minimized immunogenicity. As heterodimerization and signaling partners for human epidermal growth factor receptor 2 (HER2), HER3/HER4 has been implicated in tumorigenic signaling and therapeutic resistance of breast cancer. In this study, we engineered T cells with a CAR consisting of the extracellular domain of heregulin-1β (HRG1β) that is a natural ligand for HER3/HER4, and evaluated the specific cytotoxicity of these CAR-T cells in cultured HER3 positive breast cancer cells and xenograft tumors...
November 10, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29113154/synergistic-inhibitory-effects-of-an-engineered-antibody-like-molecule-atf-fc-and-trastuzumab-on-tumor-growth-and-invasion-in-a-human-breast-cancer-xenograft-mouse-model
#7
Hongwei Zhou, Hongwei Wang, Guangyuan Yu, Zhihong Wang, Xi Zheng, Haifeng Duan, Junzhong Sun
The overexpression of the oncogene human epidermal growth factor receptor 2 (HER-2) has been associated with decreased disease-free survival and is a marker of poor prognosis of invasive breast cancer. Although the high efficacy of trastuzumab, a drug that targets the HER-2 oncogene, has been widely recognized, the efficiency of the treatment remains at ~30%. Therefore, novel effective treatments are required for patients with recurrent metastatic breast cancer. The present study aimed to investigate the effects of an engineered antibody-like molecule administered alone or in combination with trastuzumab on the tumor growth and metastasis of HER-2-positive breast cancer...
November 2017: Oncology Letters
https://www.readbyqxmd.com/read/29105559/the-in-vitro-study-of-her-2-targeted-gold-nanoshell-liquid-fluorocarbon-poly-lactic-co-glycolic-acid-ultrasound-microcapsule-for-ultrasound-imaging-and-breast-tumor-photothermal-therapy
#8
Yu Zhang, Cai-Feng Wan, Jing Du, Qi Dong, Yuan-Yuan Wang, Hong Yang, Feng-Hua Li
Antibody-mediated targeting therapy has been successful in treating patients with breast cancer by improving the specificity and clinical efficacy. In this study, we constructed the human epidermal growth factor receptor-2 (Her2) antibody-conjugated ultrasound contrast agent with lactic-co-glycolic acid (PLGA) as film forming and perfluorocty bromide (PFOB) as internal material, which was coated by gold nanoshell (Her2-PFOB@PLGA@Au), to realize the integration of diagnosis and treatment. The contrast agent was spherical, with the diameter was 256...
November 4, 2017: Journal of Biomaterials Science. Polymer Edition
https://www.readbyqxmd.com/read/29092024/characterization-of-male-breast-cancer-results-of-the-eortc-10085-tbcrc-big-nabcg-international-male-breast-cancer-program
#9
F Cardoso, J M S Bartlett, L Slaets, C H M van Deurzen, E van Leeuwen-Stok, P Porter, B Linderholm, I Hedenfalk, C Schröder, J Martens, J Bayani, C van Asperen, M Murray, C Hudis, L Middleton, J Vermeij, K Punie, J Fraser, M Nowaczyk, I T Rubio, S Aebi, C Kelly, K J Ruddy, E Winer, C Nilsson, L Dal Lago, L Korde, K Benstead, O Bogler, T Goulioti, A Peric, S Litière, K C Aalders, C Poncet, K Tryfonidis, S H Giordano
Background: Male breast cancer (BC) is rare, managed by extrapolation from female BC. The International Male BC Program aims to better characterize and manage this disease. We report the results of part 1, a retrospective-joint-analysis of cases diagnosed during a 20-year-period. Methods: Patients with follow-up and tumor samples, treated between 1990-2010, in 93 centers/nine countries. Samples were centrally analyzed in three labs (UK, NL, US). Results: Of 1822 patients enrolled, 1483 were analyzed; 63...
October 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29089281/influence-of-biologic-subtype-of-inflammatory-breast-cancer-on-response-to-neoadjuvant-therapy-and-cancer-outcomes
#10
Tina J Hieken, Brittany L Murphy, Judy C Boughey, Amy C Degnim, Katrina N Glazebrook, Tanya L Hoskin
BACKGROUND: Few data exist on the influence of tumor biologic subtype on treatment response and outcomes for inflammatory breast cancer (IBC). We examined a contemporary cohort of IBC patients treated with current targeted systemic therapies, selected on the basis of tumor biologic subtype, to evaluate pathologic treatment response and cancer outcomes across biologic subtypes. PATIENTS AND METHODS: We studied 57 clinical stage T4dM0 IBC patients operated on at our institution from October 2008 to July 2015...
October 7, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29084234/quantifying-her-2-expression-on-circulating-tumor-cells-by-accept
#11
Leonie Zeune, Guus van Dalum, Charles Decraene, Charlotte Proudhon, Tanja Fehm, Hans Neubauer, Brigitte Rack, Marianna Alunni-Fabbroni, Leon W M M Terstappen, Stephan A van Gils, Christoph Brune
Circulating tumor cells (CTCs) isolated from blood can be probed for the expression of treatment targets. Immunofluorescence is often used for both the enumeration of CTC and the determination of protein expression levels related to treatment targets. Accurate and reproducible assessment of such treatment target expression levels is essential for their use in the clinic. To enable this, an open source image analysis program named ACCEPT was developed in the EU-FP7 CTCTrap and CANCER-ID programs. Here its application is shown on a retrospective cohort of 132 metastatic breast cancer patients from which blood samples were processed by CellSearch® and stained for HER-2 expression as additional marker...
2017: PloS One
https://www.readbyqxmd.com/read/29083340/nab-paclitaxel-after-docetaxel-hypersensitivity-reaction-case-report-and-literature-review
#12
Benedetta Pellegrino, Daniela Boggiani, Chiara Tommasi, Dante Palli, Antonino Musolino
Taxanes, including paclitaxel and docetaxel, are one of the most active cytotoxic agents in breast cancer  treatment  including  Her-2  positive  subtype characterized  by  aggressive  clinical  and pathological features since the early stage. However, their use is sometimes limited by the occurrence of hypersensivity reactions (HSRs) characterized by erythematous rashes, bronchospasm, respiratory distress, hypotension, and pulmonary edema. Cross-reactions between paclitaxel and docetaxel are described in literature with a rate ranging from 49% to 90%...
October 23, 2017: Acta Bio-medica: Atenei Parmensis
https://www.readbyqxmd.com/read/29071122/diagnostic-algorithm-prognostic-factors-and-surgical-treatment-of-metastatic-cancer-diseases-of-the-long-bones-and-spine
#13
REVIEW
Miklós Szendrői, Imre Antal, Attila Szendrői, Áron Lazáry, Péter Pál Varga
Oncological management of skeletal metastases has changed dramatically in the last few decades. A significant number of patients survive for many years with their metastases.Surgeons are more active and the technical repertoire is broader, from plates to intramedullary devices to (tumour) endoprostheses.The philosophy of treatment should be different in the case of a trauma-related fracture and a pathological fracture. A proper algorithm for establishing a diagnosis and evaluation of prognostic factors helps in planning the surgical intervention...
September 2017: EFORT open reviews
https://www.readbyqxmd.com/read/29069787/proteasome-inhibitors-prevent-bi-directional-her2-estrogen-receptor-cross-talk-leading-to-cell-death-in-endocrine-and-lapatinib-resistant-her2-er-breast-cancer-cells
#14
Sonja Thaler, Marcus Schmidt, Sven Roβwag, Gitta Thiede, Arno Schad, Jonathan P Sleeman
Amplification and/or overexpression of the human epidermal growth factor 2 (HER2) oncogene occurs in about 13-15% of invasive breast cancer and triggers breast cancer cell proliferation, survival and metastatic progression. Around half of all breast cancers with HER2 overexpression co-express hormone receptors (HR) such as those for estrogen and progesterone. Aberrant signaling through HER2 and other members of the HER-family mediates endocrine-resistance in estrogen receptor alpha (ERα) positive breast cancer...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29067051/correlation-between-the-expression-of-topo-ii%C3%AE-and-ki67-in-breast-cancer-and-its-clinical-pathological-characteristics
#15
Jihai Jin, Dongxing Zheng, Yujuan Liu
OBJECTIVE: To investigate the expression of Topo IIα and Ki67 and its clinical significance. METHODS: The clinical pathological data of one hundred and sixteen invasive breast cancer patients who were admitted into our hospital from July 2013 to December 2015 and underwent radical mastectomy were retrospectively analyzed. The expression of topoisomerase (Topo) IIα and Ki67 was detected using immunohistochemical method, and the correlation between the two kinds of proteins and the general clinical pathological characteristics of the patients was analyzed...
July 2017: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/29057208/the-efficacy-of-neoadjuvant-chemotherapy-for-her-2-positive-locally-advanced-breast-cancer-and-survival-analysis
#16
Wei Zhang, Huan Tian, Shi-Hong Yang
To provide reference data, we retrospectively investigated the effects of neoadjuvant chemotherapy (NAC) on 119 patients with HER-2(+) locally advanced breast cancer, treated from November 2010 to July 2016, with respect to influencing factors and survival. They were divided into the pathological complete response (pCR; n = 15; 12.6%) and non-pCR (n = 104; 87.4%) groups. We used Χ(2) and logistic tests to the analyze effect and influencing factors. Survival rate was analyzed by the Kaplan-Meier method and Log-rank test...
2017: Analytical Cellular Pathology (Amsterdam)
https://www.readbyqxmd.com/read/29052527/negative-genic-switch-of-her-2-in-the-primary-tumor-instead-of-the-synchronous-metastatic-nodal-lesions-after-neoadjuvant-chemotherapy-in-a-patient-with-primary-her2-positive-breast-cancer
#17
Hao-Ran Chen, Yu-Tuan Wu, Qiu-Bo Yu, Ya-Ying Yang, Yu-Xian Wei, Hong-Yuan Li, Kai-Nan Wu, Ling-Quan Kong
BACKGROUND: A few retrospective studies have indicated that neoadjuvant chemotherapy (NAC) in breast cancer may change biomarker profiles of the primary tumor. Little is known about the status of HER-2 gene of the synchronous nodal metastases when that of the residual tumor undergoes negative conversion in a neoadjuvant setting. CASE PRESENTATION: We describe a female patient with left breast cancer (T2N2M0) who underwent negative conversion of HER-2 in the primary tumor instead of the synchronous nodal lesions after NAC...
October 19, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29045452/prospective-multicenter-french-study-evaluating-the-clinical-impact-of-the-breast-cancer-intrinsic-subtype-prosigna%C3%A2-test-in-the-management-of-early-stage-breast-cancers
#18
MULTICENTER STUDY
Delphine Hequet, Céline Callens, David Gentien, Benoit Albaud, Marie-Ange Mouret-Reynier, Coraline Dubot, Paul Cottu, Cyrille Huchon, Sonia Zilberman, Helene Berseneff, Cyril Foa, Rémy Salmon, Aurélie Roulot, Florence Lerebours, Anne Salomon, Nadeem Ghali, Pascale Morel, Qianyi Li, Anne Cayre, Jean-Marc Guinebretière, John Hornberger, Frédérique Penault-Llorca, Roman Rouzier
PURPOSE: The Prosigna® breast cancer prognostic gene signature assay identifies a gene-expression profile that permits the classification of tumors into subtypes and gives a score for the risk of recurrence (ROR) at 10 years. The primary objective of this multicenter study was to evaluate the impact of Prosigna's assay information on physicians' adjuvant treatment decisions in patients with early-stage breast cancer. Secondary objectives were to assess confidence of practitioners in their therapeutic recommendations before and after the added information provided by the Prosigna assay; and to evaluate the emotional state of patients before and after the Prosigna test results...
2017: PloS One
https://www.readbyqxmd.com/read/29042085/advances-in-the-management-of-her2-positive-early-breast-cancer
#19
REVIEW
José Baselga, Robert E Coleman, Javier Cortés, Wolfgang Janni
While trastuzumab is firmly established as the cornerstone of therapy for both early and advanced breast cancer expressing human epidermal growth factor receptor 2 (HER2), many patients either do not respond to trastuzumab treatment or progress following therapy. Improved understanding of breast cancer biology, particularly the complex signaling interactions managed by the HER family of receptors, have resulted in development of several novel HER2-directed therapies and combinations. This article will review the novel approaches to HER2 targeting that have been developed in recent years, with particular focus on results from these approaches in early breast cancer, and will discuss strategies to improve the tolerability of HER2-directed therapies, including prevention of cardiac toxicity and diarrhea...
November 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29039492/black-rice-derived-anthocyanins-inhibit-her-2-positive-breast-cancer-epithelial-mesenchymal-transition-mediated-metastasis-in%C3%A2-vitro-by-suppressing-fak-signaling
#20
Jie Zhou, Yan-Feng Zhu, Xiang-Yan Chen, Bin Han, Fei Li, Jing-Yao Chen, Xiao-Li Peng, Li-Ping Luo, Wei Chen, Xiao-Ping Yu
This study aimed to investigate the role of focal adhesion kinase (FAK) signaling in the inhibitory effects of black rice anthocyanins (BRACs) on human epidermal growth factor receptor-2 (HER-2)-positive human breast cancer cell metastasis, using the MCF-10A, MCF-7 and MDA-MB-453 cells. BRACs exerted an anti-metastatic effect on the HER-2-positive breast cancer cells. The effects of BRACs on the proliferation of the MDA-MB-453 cells were examined by cell counting kit-8 assay. A wound-healing assay was used to examine the effects of BRACs on the migration of the breast cancer cells...
October 11, 2017: International Journal of Molecular Medicine
keyword
keyword
36131
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"